Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
45 hedge funds and large institutions have $14.6M invested in Aevi Genomic Medicine Inc in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 10 closing their positions.
16% more capital invested
Capital invested by funds: $12.6M → $14.6M (+$2M)
8% less funds holding
Funds holding: 49 → 45 (-4)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.64M |
| 2 |
Renaissance Technologies
New York
|
+$107K |
| 3 |
VAM
Verity Asset Management
Durham,
North Carolina
|
+$19.8K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$18.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$14.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$671K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$278K |
| 3 |
2L
22NW LP
Seattle,
Washington
|
-$195K |
| 4 |
NCMW
Northern Capital Management (Wisconsin)
Madison,
Wisconsin
|
-$192K |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$74K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| – | +$83 | +61 | New |
|
52
CIBC Private Wealth Group
Atlanta,
Georgia
| – | +$273 | +200 | New |
|
GNMX Hedge Fund Activity: Q4 2017 in Review
45 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2017, worth a combined $14.6M — up 16% from $12.6M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GNMX and 7 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 9 added.
The largest buyer was Adage Capital Partners, adding an estimated $4.64M. The largest seller was Baker Bros. Advisors, cutting an estimated $671K.
- 45 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2017, down from 49 in Q3 2017.
- Funds reported $14.6M of Aevi Genomic Medicine Inc stock for Q4 2017, up 16% quarter-over-quarter.
- 7 funds opened new Aevi Genomic Medicine Inc positions in Q4 2017 and 10 closed out, a net change of -3 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q4 2017 was Adage Capital Partners, an estimated $4.64M added.
- The largest Aevi Genomic Medicine Inc seller in Q4 2017 was Baker Bros. Advisors, an estimated $671K sold.
Based on aggregated 13F filings for Q4 2017.